Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (24)

2024

  1. Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)

    Nature Communications

  2. Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)

    Nature Communications

  3. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433

  4. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

    Nature Communications, Vol. 15, Núm. 1

2022

  1. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

  2. The Inflammatory Pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF-α Hypothesis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

  2. The Authors Reply PMC and PMT: Real Medicine and Not Just Biology

    American Journal of Surgical Pathology

2020

  1. GFRα 1-2-3-4 co-receptors for RET Are co-expressed in Pituitary Stem Cells but Individually Retained in Some Adenopituitary Cells

    Frontiers in Endocrinology, Vol. 11

  2. Molecular profiling for acromegaly treatment: a validation study

    Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389

  3. Thyroid papillary microtumor: Validation of the (updated) porto proposal assessing sex hormone receptor expression and mutational BRAF gene status

    American Journal of Surgical Pathology, Vol. 44, Núm. 9, pp. 1161-1172

  4. Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial

    Cells, Vol. 9, Núm. 4

2018

  1. Early evolutionary divergence between papillary and anaplastic thyroid cancers

    Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460

2017

  1. Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer

    Oncogene, Vol. 36, Núm. 5, pp. 652-666

  2. The syndrome of central hypothyroidism and macroorchidism: IGSF1 controls TRHR and FSHB expression by differential modulation of pituitary TGFβ and Activin pathways

    Scientific Reports, Vol. 7

2014

  1. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF

    Endocrinology, Vol. 155, Núm. 11, pp. 4329-4340

2013

  1. Sirt1 inhibits the transcription factor CREB to regulate pituitary growth hormone synthesis

    FASEB Journal, Vol. 27, Núm. 4, pp. 1561-1571

2012

  1. Defining stem cell types: Understanding the therapeutic potential of ESCs, ASCs, and iPS cells

    Journal of Molecular Endocrinology, Vol. 49, Núm. 2

2010

  1. New insights into thyroglobulin pathophysiology revealed by the study of a family with congenital goiter

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 7, pp. 3522-3526

2008

  1. Pendred syndrome in two Galician families: Insights into clinical phenotypes through cellular, genetic, and molecular studies

    Journal of Clinical Endocrinology and Metabolism, Vol. 93, Núm. 1, pp. 267-277